| Released | Contributor | Author | Title | Pages | Price |
| 30-Nov-2009 | Wall Street Transcript ,The | The Wall St Transcript | MANAGEMENT TURNOVER REPORT - Neurogesx, Inc. (NGSX) | 7 |
$50 |
| 30-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for NGSX | 13 |
$25 |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Biotechnology Intelligence Monitor: overall outlook STRONG - 25 new Leaders; 18 new Laggards. | 58 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| NeurogesX Inc | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | NEUROGESX INC (NGSX=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | NEUROGESX INC (NGSX=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ADLR , BIOD , INFI , JAV , KERX , MBRK , NGSX , SNTA -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: NEUROGESX -- NGSX | 1 |
$4 |
| 23-Nov-2009 | Market Edge |
N/A
| Market Edge Equity Research Report | 4 |
$10 |
| 17-Nov-2009 | Roth Capital Partners, Inc. | Research Department | Morning Call Summary | 11 |
$25 |
1.44% Nasdaq 
Research Reports
